August 1988
Volume 29, Issue 8
Free
Articles  |   August 1988
Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection.
Author Affiliations
  • M M Moon
    Department of Anatomy/Cell Biology, Wayne State University School of Medicine, Detroit, Michigan 48201.
  • L D Hazlett
    Department of Anatomy/Cell Biology, Wayne State University School of Medicine, Detroit, Michigan 48201.
  • R E Hancock
    Department of Anatomy/Cell Biology, Wayne State University School of Medicine, Detroit, Michigan 48201.
  • R S Berk
    Department of Anatomy/Cell Biology, Wayne State University School of Medicine, Detroit, Michigan 48201.
  • R Barrett
    Department of Anatomy/Cell Biology, Wayne State University School of Medicine, Detroit, Michigan 48201.
Investigative Ophthalmology & Visual Science August 1988, Vol.29, 1277-1284. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M M Moon, L D Hazlett, R E Hancock, R S Berk, R Barrett; Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection.. Invest. Ophthalmol. Vis. Sci. 1988;29(8):1277-1284.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
This content is PDF only. Please click on the PDF icon to access.
Abstract

A panel of well characterized monoclonal antibodies (MAbs) directed against outer membrane proteins H2, or F (porin) of Pseudomonas aeruginosa were examined to determine whether they exhibited any protective effect against subsequent ocular challenge with the bacteria topically applied to the scarified corneal surface. Mice were observed macroscopically following bacterial challenge and the degree of ocular disease graded on a scale of 0 to 4 (0, normal, fully protected cornea; 4, corneal perforation or phthisis, not protected). Mice treated intravenously with either MAb MA1-6 (anti-H2) or MA2-10 (anti-F), or a combination of these two MAbs and MAb MA4-4 (anti-F), two hours before corneal challenge with the viable bacteria, exhibited significantly less corneal disease than mice either not treated with the MAbs, treated with MA4-4 alone or treated with MAb MA1-3 (anti-I). The latter MAb is directed against an outer membrane epitope that is not surface exposed. Light and transmission electron microscopic histopathology also was employed and provided confirmatory evidence to support the macroscopic analyses.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×